Kintara Therapeutics (FRA:3DMA) Change In Inventory : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Change In Inventory?

Kintara Therapeutics's change in inventory for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Kintara Therapeutics's inventory stayed the same from Mar. 2024 to Jun. 2024 .

Kintara Therapeutics's change in inventory for the fiscal year that ended in Jun. 2024 was €0.00 Mil. It means Kintara Therapeutics's inventory stayed the same from Jun. 2023 to Jun. 2024 .

Kintara Therapeutics's Total Inventories for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kintara Therapeutics Change In Inventory Historical Data

The historical data trend for Kintara Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Change In Inventory Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Inventory

Get a 7-Day Free Trial

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Kintara Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Kintara Therapeutics (FRA:3DMA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kintara Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kintara Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kintara Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Kintara Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (FRA:3DMA) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines